CN116516009B - Amplification primer group for detecting pheochromocytoma and paraganglioma pathogenic genes and application thereof - Google Patents
Amplification primer group for detecting pheochromocytoma and paraganglioma pathogenic genes and application thereof Download PDFInfo
- Publication number
- CN116516009B CN116516009B CN202310504616.1A CN202310504616A CN116516009B CN 116516009 B CN116516009 B CN 116516009B CN 202310504616 A CN202310504616 A CN 202310504616A CN 116516009 B CN116516009 B CN 116516009B
- Authority
- CN
- China
- Prior art keywords
- amplification
- primer
- paraganglioma
- pheochromocytoma
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003321 amplification Effects 0.000 title claims abstract description 64
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 64
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 42
- 230000001717 pathogenic effect Effects 0.000 title claims abstract description 28
- 208000007312 paraganglioma Diseases 0.000 title claims abstract description 24
- 208000028591 pheochromocytoma Diseases 0.000 title claims abstract description 22
- 206010061332 Paraganglion neoplasm Diseases 0.000 title claims abstract description 21
- 108020004414 DNA Proteins 0.000 claims description 25
- 238000012163 sequencing technique Methods 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 14
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 claims description 11
- 102100033254 Tumor suppressor ARF Human genes 0.000 claims description 11
- 102100029974 GTPase HRas Human genes 0.000 claims description 10
- 101000881648 Homo sapiens Egl nine homolog 1 Proteins 0.000 claims description 10
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims description 10
- 101001033820 Homo sapiens Malate dehydrogenase, mitochondrial Proteins 0.000 claims description 10
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 10
- 101000951145 Homo sapiens Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Proteins 0.000 claims description 10
- 101000685323 Homo sapiens Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Proteins 0.000 claims description 10
- 101000874160 Homo sapiens Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 claims description 10
- 101000637950 Homo sapiens Transmembrane protein 127 Proteins 0.000 claims description 10
- 102100039742 Malate dehydrogenase, mitochondrial Human genes 0.000 claims description 10
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 10
- 102100038014 Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Human genes 0.000 claims description 10
- 102100023155 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Human genes 0.000 claims description 10
- 102100035726 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Human genes 0.000 claims description 10
- 102100032072 Transmembrane protein 127 Human genes 0.000 claims description 10
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 claims description 10
- 101150020330 ATRX gene Proteins 0.000 claims description 9
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims description 9
- 102100037249 Egl nine homolog 1 Human genes 0.000 claims description 9
- 102100036448 Endothelial PAS domain-containing protein 1 Human genes 0.000 claims description 9
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims description 9
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims description 9
- 108091059596 H3F3A Proteins 0.000 claims description 9
- 102100039236 Histone H3.3 Human genes 0.000 claims description 9
- 102100027768 Histone-lysine N-methyltransferase 2D Human genes 0.000 claims description 9
- 101001008894 Homo sapiens Histone-lysine N-methyltransferase 2D Proteins 0.000 claims description 9
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims description 9
- 101000971697 Homo sapiens Kinesin-like protein KIF1B Proteins 0.000 claims description 9
- 101000934888 Homo sapiens Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Proteins 0.000 claims description 9
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims description 9
- 102100021524 Kinesin-like protein KIF1B Human genes 0.000 claims description 9
- 108010085793 Neurofibromin 1 Proteins 0.000 claims description 9
- 102100025393 Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Human genes 0.000 claims description 9
- 102100023931 Transcriptional regulator ATRX Human genes 0.000 claims description 9
- 108700042462 X-linked Nuclear Proteins 0.000 claims description 9
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 claims description 9
- 102100037964 E3 ubiquitin-protein ligase RING2 Human genes 0.000 claims description 8
- 101001095815 Homo sapiens E3 ubiquitin-protein ligase RING2 Proteins 0.000 claims description 8
- 101001057193 Homo sapiens Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Proteins 0.000 claims description 8
- 101000582631 Homo sapiens Menin Proteins 0.000 claims description 8
- 101000881650 Homo sapiens Prolyl hydroxylase EGLN2 Proteins 0.000 claims description 8
- 101000740048 Homo sapiens Ubiquitin carboxyl-terminal hydrolase BAP1 Proteins 0.000 claims description 8
- 101000740049 Latilactobacillus curvatus Bioactive peptide 1 Proteins 0.000 claims description 8
- 102000007530 Neurofibromin 1 Human genes 0.000 claims description 8
- 102100037248 Prolyl hydroxylase EGLN2 Human genes 0.000 claims description 8
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 7
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 7
- 238000010276 construction Methods 0.000 claims description 6
- -1 SDHAF Proteins 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 102000002717 c-Mer Tyrosine Kinase Human genes 0.000 claims 2
- 206010073150 Multiple endocrine neoplasia Type 1 Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 25
- 238000007481 next generation sequencing Methods 0.000 abstract 2
- 238000012165 high-throughput sequencing Methods 0.000 abstract 1
- 102000053602 DNA Human genes 0.000 description 23
- 238000000034 method Methods 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000000523 sample Substances 0.000 description 17
- 230000035772 mutation Effects 0.000 description 12
- 238000005457 optimization Methods 0.000 description 11
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 8
- 102100022356 Tyrosine-protein kinase Mer Human genes 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 6
- 102100031715 Succinate dehydrogenase assembly factor 2, mitochondrial Human genes 0.000 description 5
- 108050007461 Succinate dehydrogenase assembly factor 2, mitochondrial Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 206010064571 Gene mutation Diseases 0.000 description 3
- 101100398309 Homo sapiens KMT2D gene Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 101150032040 KMT2D gene Proteins 0.000 description 3
- 102100030550 Menin Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- KIAPWMKFHIKQOZ-UHFFFAOYSA-N 2-[[(4-fluorophenyl)-oxomethyl]amino]benzoic acid methyl ester Chemical group COC(=O)C1=CC=CC=C1NC(=O)C1=CC=C(F)C=C1 KIAPWMKFHIKQOZ-UHFFFAOYSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 101150054061 BAP1 gene Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101150094082 KIF1B gene Proteins 0.000 description 1
- 101150018298 MAX gene Proteins 0.000 description 1
- 101150019925 MDH2 gene Proteins 0.000 description 1
- 102100027096 Nucleotide exchange factor SIL1 Human genes 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101150077555 Ret gene Proteins 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 101710145783 TATA-box-binding protein Proteins 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 108091008690 chemoreceptors Proteins 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 208000029532 parasympathetic paraganglioma Diseases 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 102220002638 rs121908983 Human genes 0.000 description 1
- 101150047761 sdhA gene Proteins 0.000 description 1
- 101150114996 sdhd gene Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The application relates to the technical field of gene detection, in particular to an amplification primer group for detecting pheochromocytoma and paraganglioma pathogenic genes and application thereof, which are suitable for high-throughput sequencing (Next Generation Sequencing, NGS).
Description
Technical Field
The application relates to the technical field of gene detection, and in particular provides an amplification primer group for detecting pathogenic genes of pheochromocytoma and paraganglioma and application thereof.
Background
Pheochromocytomas and paragangliomas (Pheochromocytoma and paraganglioma, PPGL) are tumors originating from neuroectodermal pheochromonas, mainly secreting catecholamines, and are classified into parasympathetic paragangliomas (including chemoreceptor tumors, carotid aneurysms, etc.) and sympathogenic paragangliomas (including retroperitoneal, pelvic and postmediastinal paragangliomas) depending on whether the tumor is from a sympathetic or parasympathetic nerve. Some patients can be endangered by serious heart, brain and kidney damage caused by long-term hypertension or crisis caused by sudden severe hypertension, but if diagnosis and treatment can be timely and early obtained, the patients are curable secondary hypertension.
At present, most detection methods for PPGL pathogenic gene mutation only comprise partial related genes, the detection range is not comprehensive enough, and the region with higher GC content or higher homology of partial pathogenic genes cannot be effectively amplified, or higher DNA initial quantity is required for detection, so that the amplification uniformity is influenced.
In view of this, the present application has been proposed.
Disclosure of Invention
In order to solve the technical problems, the application aims to provide a method or a system for detecting PPGL pathogenic genes, which has the advantages of comprehensive detection, low sample initial quantity requirement, high amplification efficiency, better accuracy and higher flux.
Accordingly, a first object of the present application is to provide a library construction method suitable for NGS for detecting pheochromocytoma and paraganglioma pathogenic genes;
a second object is to provide a method for detecting pheochromocytoma and paraganglioma pathogenic genes which can fully contain PPGL pathogenic genes;
the third object of the application is to provide a primer group for detecting pathogenic genes of pheochromocytoma and paraganglioma, and a composition or a kit thereof.
Specifically, the technical scheme adopted by the application is as follows:
the application firstly provides a library construction method for detecting pathogenic genes of pheochromocytoma and paraganglioma, which is applicable to NGS, and the following is exemplified by Ion torrent platform sequencing, and is characterized by comprising the following steps:
1) Extracting sample DNA;
2) Library amplification: amplifying the extracted DNA;
3) And (3) joint connection: sequencing the amplified products and connecting the sequencing joints;
4) And (5) purifying the library.
Further, the amplification in 1) is performed for VHL, SDHA, SDHB, SDHC, SDHD, NF1, FH, MAX, TMEM127, RET, MET, KIF1B, SDHAF2, EPAS1, EGLN1, MDH2, KMT2D, TP, H3F3A, HRAS, IDH2, ATRX, BRAF, EGLN2, FGFR1, MERTK, CDKN2A, BAP1 and MEN1 genes.
Further, the amplification in 1) is performed for INDELs within SNV and 22bp of CDs region and variable cleavage region of VHL, SDHA, SDHB, SDHC, SDHD, NF1, FH, MAX, TMEM127, RET, MET, KIF1B, SDHAF2, EPAS1, EGLN1, MDH2, KMT2D, TP, H3F3A, HRAS, IDH2, ATRX, BRAF, EGLN2, FGFR1, MERTK, CDKN2A, BAP1 and MEN1 genes.
Further, the amplification primer sequence is shown as SEQ ID NO. 1-650.
Further, the amplification conditions were as follows:
further, the library amplification step of 2) is specifically as follows:
Pre-Mix was prepared for a total of 2 pool, 5ul per reaction, with the following formulation method:
split charging is carried out on the prepared Pre-Mix, genomic DNA is added, and a reaction system is prepared as follows:
covering the tube cover, gently swirling, mixing, and centrifuging briefly, wherein bubbles are generated (if bubbles are generated, the tube wall is flicked, and the bubbles are broken and then separated instantaneously); the prepared reaction system is put into a PCR instrument, and the following procedure is started for amplification:
further, the 3) joint connection step is specifically as follows:
putting all products of pool1 into pool2 correspondingly, adding 1 μl FuPa Reagent into each PCR product, covering with a cover, mixing, and centrifuging instantaneously to prevent bubbles (if bubbles are generated, flicking the tube wall, breaking the bubbles and then instantaneously separating); the mixed reactants are put into a PCR instrument, and the following procedure is started for reaction:
barcode adapter Mix is formulated according to the following table
Configuring the sample to establish a corresponding relation between the sample name and the Barcode adapter, and preparing a joint connection system according to the following table:
adding 1 μl of DNA (deoxyribonucleic acid) Ligase into the reaction system, covering with a cover, mixing, and performing instantaneous centrifugation to prevent bubbles (if bubbles are generated, flicking the tube wall to break the bubbles, and then instantaneously separating); the prepared reaction system is put into a PCR instrument, and the following procedure is started for reaction:
the application also provides a detection method of pheochromocytoma and paraganglioma, comprising any one of the library construction methods, and further comprising the steps of sequencing and belief analysis by NGS.
The application also provides a primer group for detecting the pathogenic genes of pheochromocytoma and paraganglioma, wherein the primer in 1) is a primer for amplifying VHL, SDHA, SDHB, SDHC, SDHD, NF1, FH, MAX, TMEM127, RET, MET, KIF1B, SDHAF2, EPAS1, EGLN1, MDH2, KMT2D, TP53, H3F3A, HRAS, IDH2, ATRX, BRAF, EGLN2, FGFR1, MERTK, CDKN2A, BAP1 and MEN1 genes.
Further, the primer is a primer for amplifying INDEL within 22bp of SNV of CDs region and variable shearing region of VHL, SDHA, SDHB, SDHC, SDHD, NF1, FH, MAX, TMEM127, RET, MET, KIF1B, SDHAF, EPAS1, EGLN1, MDH2, KMT2D, TP53, H3F3A, HRAS, IDH2, ATRX, BRAF, EGLN2, FGFR1, MERTK, CDKN2A, BAP1 and MEN1 genes.
Further, the primer sequence is shown as SEQ ID NO. 1-650.
The application also provides a composition comprising any one of the primer sets.
The application also provides a kit for detecting pathogenic genes of pheochromocytoma and paraganglioma, which comprises any one of the primer groups.
The application also provides application of any one of the primer groups or the composition in preparation of a kit for detecting pheochromocytoma and paraganglioma library construction or a pathogenic gene detection kit.
Compared with the prior art, the application has at least the following advantages:
1) According to the application, 29 genes of VHL, SDHA, SDHB, SDHC, SDHD, NF1, FH, MAX, TMEM127, RET, MET, KIF1B, SDHAF, EPAS1, EGLN1, MDH2, KMT2D, TP53, H3F3A, HRAS, IDH2, ATRX, BRAF, EGLN2, FGFR1, MERTK, CDKN2A, BAP and MEN1 are determined as detection target pathogenic genes through screening, three levels of basically, expanding and synthesizing are covered, and the CDs region of the pathogenic genes and the INDEL within SNV and 22bp of the variable shearing region are further detected, so that the method can be effectively used for detecting pheochromocytoma and paraganglioma diseases through high-throughput gene sequencing, and has the advantages of comprehensive detection, high accuracy and the like.
2) The application solves the problem that partial gene areas cannot be effectively amplified due to high GC content or high homology by optimizing and matching the primer sequences and the reaction system, and ensures the effectiveness of an ultra-high-weight amplification system, improves the amplification efficiency and has better data uniformity on the premise of low initial quantity of 20ng DNA.
3) The application provides an overall solution for refractory hypertension molecular diagnosis and differential diagnosis, which has the advantages of simple operation, high flux, comprehensive detection, high accuracy and the like.
Drawings
In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings that are needed in the description of the embodiments or the prior art will be briefly described, and it is obvious that the drawings in the description below are some embodiments of the present application, and other drawings can be obtained according to the drawings without inventive effort for a person skilled in the art.
FIG. 1, amplification efficiencies of different GC content regions under conventional amplification conditions;
FIG. 2, amplification efficiency of different GC content regions in an optimized amplification primer set application;
FIG. 3 shows the results of detection of pathogenic mutation sites and one-generation sequencing verification of the present application.
Detailed Description
The following description of the embodiments of the present application will be made apparent and fully in view of the accompanying drawings, in which some, but not all embodiments of the application are shown. All other embodiments, which can be made by those skilled in the art based on the embodiments of the application without making any inventive effort, are intended to be within the scope of the application.
The following terms or definitions are provided solely to aid in the understanding of the application. These definitions should not be construed to have a scope less than understood by those skilled in the art.
Unless defined otherwise hereinafter, all technical and scientific terms used in the detailed description of the application are intended to be identical to what is commonly understood by one of ordinary skill in the art. While the following terms are believed to be well understood by those skilled in the art, the following definitions are set forth to better explain the present application.
As used herein, the terms "comprising," "including," "having," "containing," or "involving" are inclusive or open-ended and do not exclude additional unrecited elements or method steps. The term "consisting of …" is considered to be a preferred embodiment of the term "comprising". If a certain group is defined below to contain at least a certain number of embodiments, this should also be understood to disclose a group that preferably consists of only these embodiments.
The indefinite or definite article "a" or "an" when used in reference to a singular noun includes a plural of that noun.
The terms "about" and "substantially" in this application mean the range of accuracy that one skilled in the art can understand yet still guarantee the technical effect of the features in question. The term generally means a deviation of + -10%, preferably + -5%, from the indicated value.
Furthermore, the terms first, second, third, (a), (b), (c), and the like in the description and in the claims, are used for distinguishing between similar elements and not necessarily for describing a sequential or chronological order. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the application described herein are capable of operation in other sequences than described or illustrated herein.
Experimental example 1 establishment of detection Gene
In the embodiment, 20 common genes VHL, SDHA, SDHB, SDHC, SDHD, NF1, FH, MAX, TMEM127, RET, MET, KIF1B, SDHAF2, EGLN1, MDH2, KMT2D, MERTK, CDKN2A, BAP1 and MEN1 are selected as gene sets for detection, but analysis shows that the detection results are incomplete easily due to the common genes, and 9 genes of EPAS1, TP53, H3F3A, HRAS, IDH2, ATRX, BRAF, EGLN2 and FGFR1 are expanded for detection through screening and exploration, so that the detection genes cover three levels of basic, expansion and comprehensive, the detection integrity is enriched, and the detection results are more comprehensive.
Experimental example 2 exploration and optimization of targeting region and primer sequences
This example was based on the genes VHL, SDHA, SDHB, SDHC, SDHD, NF, FH, MAX, TMEM127, RET, MET, KIF1B, SDHAF2, EPAS1, EGLN1, MDH2, KMT2D, TP53, H3F3A, HRAS, IDH2, ATRX, BRAF, EGLN2, FGFR1, MERTK, CDKN2A, BAP1 and MEN1 determined in example 1, and primer amplification was performed with the CDs region and variable sheared region of these target genes, and by analysis, the present application selected amplification assays for SNV and INDEL of length within 22bp for these genes, thereby obtaining more favorable pathogenic mutation information.
This example designs amplification primers for the above regions and optimizes the final primer targeting region and primer sequence, etc. The spread is for reasons of coverage only.
The method comprises the following steps: table 1 shows the coverage of the target region before optimization, and the example adds the primers SEQ ID NO.53-54 to ensure that the exon1 region of the EGLN1 gene reaches 100% coverage; the primers of SEQ ID NO.293-294 are added to ensure that the exo 1 region of the MDH2 gene reaches 100% coverage; the SEQ ID NO.257-258 primer is added, so that the exon10 region of the KMT2D gene reaches 100% coverage; the SEQ ID NO.193-194 primer is added, so that the exon42 region of the KMT2D gene reaches 100% coverage; the primers of SEQ ID NO.635-636 were optimized to achieve 100% coverage of the exon4 region of the SDHD gene (see in particular Table 3).
In addition, the application adjusts the base sequence of the primer sequence for the problem of poor coverage caused by poor amplification effect of the original primer. Table 2 shows the original primer sequences, and the primers SEQ ID NO.563-564 are obtained by optimizing and adjusting part of the original sequences, so that the exon1 region of the SDHA gene reaches 100% amplification coverage; optimizing to obtain SEQ ID NO.199-200 primer, so that the exon39 region of the KMT2D gene reaches 100% amplification coverage; optimizing to obtain SEQ ID NO.23-24 primer to ensure that the exon6 region of the BAP1 gene reaches 100% amplification coverage; optimizing to obtain a primer of SEQ ID NO.159-160, so that the exon45 region of the KIF1B gene reaches 100% amplification coverage; optimizing to obtain SEQ ID NO.283-284 primer to make the exon4 region of MAX gene reach 100% amplification coverage; the primers SEQ ID NO.531-532 are obtained by optimization, so that the exon5 region of RET gene reaches 100% amplification coverage, and the sequence before primer optimization is shown in Table 2. After the above optimization, the target area reached 100% coverage, see in particular table 3.
TABLE 1 target area coverage Condition before primer optimization
TABLE 2 primer sequences before partial optimization
TABLE 3 target area coverage after primer optimization
Through the optimization, the application finally determines the primer sequence as follows:
/>
/>
/>
/>
/>
example 3 optimization of amplification System
In this example, 1 clinical sample diagnosed positive was selected, the amplification primer set was used to amplify the target region and sequenced by NGS, the coverage of the amplified region in the sequencing result was analyzed, and the amplification efficiency of the amplification primer set and the rationality of the test method were evaluated. The operation flow is as follows:
1) Extracting sample DNA according to a conventional process;
2) Amplifying the DNA obtained in the step one according to a conventional test flow, and sequencing by using NGS, wherein the test amplification conditions are as follows:
3) Counting data coverage information to obtain a target area coverage result;
4) The reason for the uncovered area was analyzed and an improvement scheme was specified.
Target area coverage results: the partial genes of the target region are not completely covered, and the high GC region cannot be amplified due to the high GC content of the partial region, so that the target region is not completely covered, and the amplification efficiency is shown in the figure 1.
The application further adjusts the test procedure, improves the amplification conditions and increases the coverage.
And (3) selecting the sample, amplifying the target region by using the amplification primer set, sequencing by NGS, analyzing the coverage of the amplified region in the sequencing result, and evaluating the amplification efficiency of the amplification primer set and the rationality of the test method. The operation flow is as follows:
1) Extracting sample DNA according to a conventional process;
2) The DNA obtained in step one was amplified according to the test procedure of the present application and sequenced using NGS. From the above results, it is clear that the amplification efficiency of the high GC content region is low, and the template is difficult to open because of the high energy required for melting due to the formation of three pairs of hydrogen bonds between G, C, and the main difficulty faced in the amplification of the high GC content template is that the stable secondary structure is easily formed in the template to prevent the DNA polymerase from advancing on the template, and a plurality of non-specific primer renaturation sites may exist on the template, resulting in non-specific amplification, even in many times no target gene is amplified. To solve this problem, the present application attempts to improve by: the cycle number of the denaturation reaction is increased, so that the denaturation reaction can be fully carried out, and the high GC content area can be thoroughly separated; setting the temperature difference between annealing and extension procedures, fully combining the primer and the template, and then performing the extension reaction of the sequence, so that the target sequence can be effectively extended. The specific conditions after improvement are:
3) Counting data coverage information to obtain a target area coverage result;
4) And comparing the coverage results, and analyzing the feasibility of the scheme.
As shown in figure 2, comparing figure 1, the application solves the coverage problem of the target area under the condition of adjusting the amplification condition, and effectively solves the problem of high GC area amplification failure.
Example 4 establishment of the inventive method System
The amplification primer set of the gene detection method for determining the final pheochromocytoma and paraganglioma diseases according to the optimization of the embodiment comprises the following steps:
1. library construction and primer amplification sequencing
1. Sample preparation: extracting DNA;
2. library amplification: pre-Mix was prepared for a total of 2 pool, 5ul per reaction, with the following formulation method:
split charging is carried out on the prepared Pre-Mix, genomic DNA is added, and a reaction system is prepared as follows:
covering the tube cover, gently swirling, mixing, and centrifuging briefly, wherein bubbles are generated (if bubbles are generated, the tube wall is flicked, and the bubbles are broken and then separated instantaneously); the prepared reaction system is put into a PCR instrument, and the following procedure is started for amplification:
3. digestion of primer, enzyme digestion and ligation to adaptor
Putting all products of pool1 into pool2 correspondingly, adding 1 μl FuPa Reagent into each PCR product, covering with a cover, mixing, and centrifuging instantaneously to prevent bubbles (if bubbles are generated, flicking the tube wall, breaking the bubbles and then instantaneously separating); the mixed reactants are put into a PCR instrument, and the following procedure is started for reaction:
barcode adapter Mix (pollution prevention) is formulated according to the following table
The configuration magnet establishes a corresponding relation between a sample name and a Barcode adapter, and a joint connection system is prepared according to the following table:
adding 1 μl of DNA (deoxyribonucleic acid) Ligase into the reaction system, covering with a cover, mixing, and performing instantaneous centrifugation to prevent bubbles (if bubbles are generated, flicking the tube wall to break the bubbles, and then instantaneously separating); the prepared reaction system is put into a PCR instrument, and the following procedure is started for reaction:
/>
4. library purification:
fresh 70% ethanol was prepared in an amount of 300ul per purification step for each sample; incubating Agencourt AMPure XP Beads in advance for half an hour at room temperature, and fully and uniformly mixing when in use; adding 22.5 mu l Agencourt AMPure XP Beads into the product obtained in the step 3, blowing and sucking the mixture, standing the mixture at room temperature for 5min, then transferring the Tube to DynaMag-2magnet, standing the Tube for more than 5min until the Tube is clear, and removing the supernatant; 150 μl of freshly prepared 70% ethanol was added to the centrifuge tube and after 2 weeks of rotation on a magnetic rack, the supernatant was carefully removed; repeating the steps, removing the supernatant, and air-drying the magnetic beads (the back surfaces of the magnetic beads are provided with a crack); adding 50 μl of low TE, blowing and sucking, mixing, standing at room temperature for 2min, centrifuging, standing in DynaMag-2Magnet until the solution is completely clear (> 3 min), transferring the supernatant into a new centrifuge tube, and completing the warehouse building.
5. Dilution and quantification (quality control) of DNA library
Library quantification was performed using Real-Time PCR (kit selection Ion Library TaqMan Quantitation Kit, instrument VII 7); firstly, diluting the standard substance according to the sequence of S1, S2 and S3, and diluting the original standard substance S0-68pM and 10 times of the original standard substance S0-68pM to 6.8pM,0.68pM and 0.068pM; the library of each sample was diluted 100-fold by 5ul and single sample quantification was performed; the reagents for qPCR were prepared according to the number of samples, in a total volume of 10ul, according to the following table:
PCR was performed under the following conditions:
2. sequencing and data analysis:
1. after library preparation and qualification, the NGS method was used to sequence, and the sequencing steps were performed according to existing protocols.
2. According to ClinVar, 1000G, HGMD, clinGen, dbVar, gnomAD etc. databases, vep is used
v96 annotates detected SNPs and INDELs, analyzing the pathogenicity of mutations against pheochromocytoma and paraganglioma diseases.
3. According to guidelines such as ACMG, the mutation is manually interpreted, pathogenic mutation is screened out, and a detection report is provided according to a pathogenicity result.
Example 5 advantage in starting amount of DNA
In PPGL-associated pathogenic genes, the GC content of 13 total regions is greater than 70%. These regions are affected in amplification efficiency, so that conventional methods require amplification using a larger initial amount of DNA in order to obtain efficient amplification. According to the application, the optimized amplification conditions are used, and all the regions can be effectively amplified only by using the same initial quantity (20 ng) of DNA as other regions, so that the high initial quantity of DNA is not required to be amplified, the original sample is saved, the influence of the high initial quantity on the amplification quality of other regions can be avoided, the amplification result is more uniform, the application is convenient, and the amplification effect is good. Amplification was performed using a starting amount of 20ng DNA, the high GC content region was fully covered, and the statistics of the high GC content region and its coverage are shown in Table 4.
TABLE 4 Gene regions with GC content of more than 70%
| Gene | Exon | GC | Coverage(Depth>＝4X) |
| SDHB | exon1 | 71.83％ | 100％ |
| FH | exon1 | 70.23％ | 100％ |
| TMEM127 | exon2 | 72.43％ | 100％ |
| MERTK | exon1 | 76.67％ | 100％ |
| VHL | exon1 | 71.98％ | 100％ |
| SDHA | exon1 | 79.03％ | 100％ |
| MDH2 | exon1 | 75.38％ | 100％ |
| BRAF | exon1 | 77.37％ | 100％ |
| CDKN2A | exon2 | 72.22％ | 100％ |
| CDKN2A | exon1 | 73.15％ | 100％ |
| RET | exon4 | 71.78％ | 100％ |
| HRAS | exon5 | 72.88％ | 100％ |
| NF1 | exon1 | 71.19％ | 100％ |
Example 6 verification of clinical sample detection and first generation sequencing
In this example, 1 patient sample was selected for clinical diagnosis of paraganglioma (heart, mediastinum, post-operation) and pheochromocytoma (bi-adrenal) recurrence after metastatic operation, target region amplification was performed using the amplification primer set and amplification system determined in example 3, and sequencing was performed by NGS, analyzing gene mutation and performing site annotation, interpreting the annotation results and determining the site of pathogenic mutation. The operation flow is as follows:
1) Extracting sample DNA according to a conventional process;
2) Amplifying the DNA obtained in the step one according to the test flow, and sequencing and mutation detection by using NGS;
3) Performing site annotation on the mutation result, reading the annotation result, and searching the mutation site of the pathogenic gene;
4) Further carrying out first-generation sequencing verification on the pathogenic mutation site.
Pathogenic mutation results: the pathogenic gene mutation of the patient is detected to be SDHD c.278_280del p.Tyr93del, the detection result is consistent with clinical symptoms, and the specific pathogenic mutation information is shown in the attached table 5.
TABLE 5 clinical diagnostic positive sample test result information
A first generation sequencing verification result is shown in figure 3, and is consistent with the detection result of the application. The above results demonstrate the accuracy and effectiveness of the present application in clinical assays.
The foregoing descriptions of specific exemplary embodiments of the present application are presented for purposes of illustration and description. It is not intended to limit the application to the precise form disclosed, and obviously many modifications and variations are possible in light of the above teaching. The exemplary embodiments were chosen and described in order to explain the specific principles of the application and its practical application to thereby enable one skilled in the art to make and utilize the application in various exemplary embodiments and with various modifications as are suited to the particular use contemplated. It is intended that the scope of the application be defined by the claims and their equivalents.
Claims (5)
1. A library construction method for NGS for detecting pheochromocytoma and paraganglioma causative genes, comprising the steps of:
1) Extracting sample DNA;
2) Library amplification: amplifying the extracted DNA;
3) And (3) joint connection: sequencing adaptor connection is carried out on the amplified products;
4) Purifying the library;
the amplification in 2) is: amplification was performed against INDELs within SNV, 22bp of the CDs region and variable cleavage region of the genes VHL, SDHA, SDHB, SDHC, SDHD, NF1, FH, MAX, TMEM127, RET, MET, KIF1B, SDHAF, EPAS1, EGLN1, MDH2, KMT2D, TP53, H3F3A, HRAS, IDH2, ATRX, BRAF, EGLN, FGFR1, MERTK, CDKN2A, BAP1 and MEN 1;
the sequence of the amplification primer is shown as SEQ ID NO. 1-650;
2. A primer set for detecting a pheochromocytoma and paraganglioma causative gene, wherein the primer is a primer for amplification against INDELs within SNV and 22bp of the CDs region and variable shear region of VHL, SDHA, SDHB, SDHC, SDHD, NF1, FH, MAX, TMEM127, RET, MET, KIF1B, SDHAF, EPAS1, EGLN1, MDH2, KMT2D, TP53, H3F3A, HRAS, IDH2, ATRX, BRAF, EGLN2, FGFR1, MERTK, CDKN2A, BAP1 and MEN1 genes; the sequence of the primer is shown as SEQ ID NO. 1-650.
3. A composition comprising the primer set of claim 2.
4. A kit for detecting a disease causing gene of pheochromocytoma and paraganglioma, comprising the primer set of claim 2.
5. Use of the primer set of claim 2 or the composition of claim 3 in the preparation of a kit for detecting pheochromocytoma and paraganglioma pathogenic genes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310504616.1A CN116516009B (en) | 2023-05-06 | 2023-05-06 | Amplification primer group for detecting pheochromocytoma and paraganglioma pathogenic genes and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310504616.1A CN116516009B (en) | 2023-05-06 | 2023-05-06 | Amplification primer group for detecting pheochromocytoma and paraganglioma pathogenic genes and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116516009A CN116516009A (en) | 2023-08-01 |
| CN116516009B true CN116516009B (en) | 2023-10-13 |
Family
ID=87397294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310504616.1A Active CN116516009B (en) | 2023-05-06 | 2023-05-06 | Amplification primer group for detecting pheochromocytoma and paraganglioma pathogenic genes and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116516009B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107304443A (en) * | 2016-04-20 | 2017-10-31 | 上海市内分泌代谢病研究所 | Storehouse PCR primer and banking process are built in the sequencing of the generation of chromaffin cell Disease-causing gene two |
| CN110484622A (en) * | 2019-08-15 | 2019-11-22 | 上海交通大学医学院附属瑞金医院 | A kind of chromaffin tissue oncogene Panel and its application |
| WO2019237425A1 (en) * | 2018-06-14 | 2019-12-19 | 大连医科大学附属第一医院 | Biomarker for early diagnosis and preoperative evaluation of pheochromocytomas/paragangliomas and use thereof |
| CN111500726A (en) * | 2020-04-30 | 2020-08-07 | 北京和合医学诊断技术股份有限公司 | Primer group for detecting pathogenic gene mutation of pheochromocytoma and paraganglioma and application method thereof |
-
2023
- 2023-05-06 CN CN202310504616.1A patent/CN116516009B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107304443A (en) * | 2016-04-20 | 2017-10-31 | 上海市内分泌代谢病研究所 | Storehouse PCR primer and banking process are built in the sequencing of the generation of chromaffin cell Disease-causing gene two |
| WO2019237425A1 (en) * | 2018-06-14 | 2019-12-19 | 大连医科大学附属第一医院 | Biomarker for early diagnosis and preoperative evaluation of pheochromocytomas/paragangliomas and use thereof |
| CN110484622A (en) * | 2019-08-15 | 2019-11-22 | 上海交通大学医学院附属瑞金医院 | A kind of chromaffin tissue oncogene Panel and its application |
| CN111500726A (en) * | 2020-04-30 | 2020-08-07 | 北京和合医学诊断技术股份有限公司 | Primer group for detecting pathogenic gene mutation of pheochromocytoma and paraganglioma and application method thereof |
Non-Patent Citations (3)
| Title |
|---|
| New methods of classification and prognosis in paragangliomas and pheochromocytomas，https://dspace.cuni.cz/handle/20.500.11956/178752;Guha, Anasuya;Digitální repozitář UK;1-87 * |
| 嗜铬细胞瘤/副神经节瘤患者RET、VHL、SDHD、SDHB遗传基因变异的检测;吴恺等;北京大学学报(医学版)(第4期);634-639 * |
| 嗜铬细胞瘤与副神经节瘤基因组学新进展;张富勋等;中国肿瘤临床(第18期);969-972 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116516009A (en) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019024598A1 (en) | Dna probe library for hybridization with micro-satellite instability related micro-satellite sites, detection method and kit | |
| JP7189401B2 (en) | Methods for preparing cell-free nucleic acid molecules by in situ amplification | |
| JP7232643B2 (en) | Deep sequencing profiling of tumors | |
| US20050037388A1 (en) | Method for detecting diseases caused by chromosomal imbalances | |
| CN101838683B (en) | Detection method of nucleotide mutation points of KRAS gene and/or BRAF gene | |
| WO2012118802A1 (en) | Kit and method for sequencing a target dna in a mixed population | |
| CN106995851B (en) | PCR primer for amplifying PKD1 exon ultra-long fragment, kit for detecting PKD1 gene mutation and application | |
| EP1930447A2 (en) | Methods and compositions for perioperative genomic profiling | |
| WO2017036374A1 (en) | Method for amplifying dna | |
| CN106755340B (en) | Method and system for carrying out Y-STR typing on male individuals by utilizing 26Y-STR loci | |
| Goold et al. | The development of sequence-tagged sites for human chromosome 4 | |
| CN111020026A (en) | Specific primer probe combination and application thereof in detection of folate metabolism capability gene by combining blood direct amplification with fluorescence PCR (polymerase chain reaction) method | |
| CN113557300A (en) | Nucleic acid sequence, RNA target region sequencing library construction method and application | |
| CN116516009B (en) | Amplification primer group for detecting pheochromocytoma and paraganglioma pathogenic genes and application thereof | |
| CN109234388B (en) | Reagent for enriching DNA hypermethylated region, enrichment method and application | |
| CN108624686B (en) | A kind of probe library, detection method and the kit of detection BRCA1/2 mutation | |
| CN113215663B (en) | Construction method of gastric cancer targeted therapy genome library based on high-throughput sequencing and primers | |
| CN113544282B (en) | Method for constructing sequencing library based on DNA sample and application | |
| CN111748621A (en) | Probe library and kit for detecting 41 genes related to lung cancer and application of probe library and kit | |
| CN105255858A (en) | Method for transforming nucleic acid genotype | |
| CN112680510B (en) | Primer pair and kit for detecting gene polymorphism related to etanercept drug administration | |
| WO2020259455A1 (en) | Method for constructing pacbio sequencing library | |
| CN117265116A (en) | Detection method, kit and probe library of TFE3 fusion gene | |
| CN116288742A (en) | Method for constructing DNA molecule library | |
| EP3696279A1 (en) | Methods for noninvasive prenatal testing of fetal abnormalities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |